The Pro Medicus Ltd (ASX: PME) share price is in focus today after the company secured a five-year, $37 million contract renewal with Northwestern Medicine, featuring increased minimum spend and higher fees per transaction.
What did Pro Medicus report?
- Signed a 5-year, $37 million contract renewal with Northwestern Medicine
- The renewal is based on transaction volume, with potential upside
- Increased minimum commitments and higher fee per exam locked in
- Nearly $80 million in contract renewals agreed in the past month
What else do investors need to know?
The renewed agreement is with Northwestern Medicine, a leading academic health system in Chicago, serving over 200 sites. The contract not only increases the minimum transaction volume but also raises the fee paid to Pro Medicus for each exam, reflecting growth since the initial agreement.
This contract builds on Pro Medicus’s strong client retention track record. The company’s Visage 7 Viewer platform is now firmly established within Northwestern Medicine, supporting both financial and clinical outcomes.
What did Pro Medicus management say?
Chief Executive Officer Dr Sam Hupert said:
We are extremely pleased that in addition to committing to a second five-year term at an increased fee per exam, NM have also committed to an increase in their minimums reflecting the growth in their exam volumes since standardising on our platform five years ago.
What’s next for Pro Medicus?
Pro Medicus continues to invest in its core imaging platform and grow its base of recurring contract revenue. Management highlighted almost $80 million in recent renewals, supporting the company’s belief in the lasting value of its technology.
The group plans to maintain its focus on client retention and further expansion in international markets, as well as ongoing innovation within its medical imaging software suite.
Pro Medicus share price snapshot
Over the past 12 months, Pro Medicus shares have declined 40%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.
The post Pro Medicus locks in 5-year, $37m Northwestern Medicine contract renewal appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- GQG Partners share price in focus as Q1 FUM update reveals outflows
- Champion Iron finalises acquisition of Norway’s Rana Gruber
- Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal
- Brambles shares: Class action judgment update
- The a2 Milk Company lowers FY26 guidance amid supply chain challenges
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.